Patients' willingness to enter clinical trials: Measuring the association with perceived benefit and preference for decision participation

Should Women at Increased Risk for Breast and Ovarian Cancer Be Randomized to Prophylactic Surgery? An Ethical and Empirical Assessment

“…In contrast to their views of RCTs, a substantial majority of the women surveyed expressed willingness to participate in NRCTs for both breast and ovarian cancer risk reduction. Consistent with previous studies, 10 our findings suggests that aversion to randomization or opposition to one arm of the trial is a key factor in PROPHYLACTIC SURGERY AND RANDOMIZED CLINICAL TRIALS 229 unwillingness to participate in RCTs. A similarly high proportion of women in our study expressed willingness to participate in registries.…”

Should Women at Increased Risk for Breast and Ovarian Cancer Be Randomized to Prophylactic Surgery? An Ethical and Empirical Assessment

“…In contrast to their views of RCTs, a substantial majority of the women surveyed expressed willingness to participate in NRCTs for both breast and ovarian cancer risk reduction. Consistent with previous studies, 10 our findings suggests that aversion to randomization or opposition to one arm of the trial is a key factor in PROPHYLACTIC SURGERY AND RANDOMIZED CLINICAL TRIALS 229 unwillingness to participate in RCTs. A similarly high proportion of women in our study expressed willingness to participate in registries.…”

Improving Recruitment in Clinical Trials: Why Eligible Participants Decline

“…In addition, there were those who declined participation because they were solely interested in outpatient studies. These findings support the limited studies that have been done in the past, which also identified protocol issues such as preference for a specific treatment arm and fear of randomization (Penman et al, 1984; Llewellyn-Thomas et al, 1991; Jenkins et al, 1999) and the dislike of treatment being based on chance (Jenkins & Fallowfield, 2000) as reasons for declining participation.…”

What are potential barriers and enablers to patient and physician participation in Canadian cell therapy trials for stroke? A stakeholder interview study

“…Perhaps surprisingly, almost all patients expressed that inclusion of a placebo group would not impact their decision to participate. This is contrary to previous literature that has reported randomisation as a potential barrier to patient recruitment 9 10 27 28. Our finding may reflect the fact that chronic stroke is an under-researched area1 and, as a result, there is a strong appetite among patients to participate in evaluations of promising new therapies.…”

Should Women at Increased Risk for Breast and Ovarian Cancer Be Randomized to Prophylactic Surgery? An Ethical and Empirical Assessment

“…In contrast to their views of RCTs, a substantial majority of the women surveyed expressed willingness to participate in NRCTs for both breast and ovarian cancer risk reduction. Consistent with previous studies, 10 our findings suggests that aversion to randomization or opposition to one arm of the trial is a key factor in PROPHYLACTIC SURGERY AND RANDOMIZED CLINICAL TRIALS 229 unwillingness to participate in RCTs. A similarly high proportion of women in our study expressed willingness to participate in registries.…”

Improving Recruitment in Clinical Trials: Why Eligible Participants Decline

“…In addition, there were those who declined participation because they were solely interested in outpatient studies. These findings support the limited studies that have been done in the past, which also identified protocol issues such as preference for a specific treatment arm and fear of randomization (Penman et al, 1984; Llewellyn-Thomas et al, 1991; Jenkins et al, 1999) and the dislike of treatment being based on chance (Jenkins & Fallowfield, 2000) as reasons for declining participation.…”

What are potential barriers and enablers to patient and physician participation in Canadian cell therapy trials for stroke? A stakeholder interview study

“…Perhaps surprisingly, almost all patients expressed that inclusion of a placebo group would not impact their decision to participate. This is contrary to previous literature that has reported randomisation as a potential barrier to patient recruitment 9 10 27 28. Our finding may reflect the fact that chronic stroke is an under-researched area1 and, as a result, there is a strong appetite among patients to participate in evaluations of promising new therapies.…”

Should Women at Increased Risk for Breast and Ovarian Cancer Be Randomized to Prophylactic Surgery? An Ethical and Empirical Assessment

“…In contrast to their views of RCTs, a substantial majority of the women surveyed expressed willingness to participate in NRCTs for both breast and ovarian cancer risk reduction. Consistent with previous studies, 10 our findings suggests that aversion to randomization or opposition to one arm of the trial is a key factor in PROPHYLACTIC SURGERY AND RANDOMIZED CLINICAL TRIALS 229 unwillingness to participate in RCTs. A similarly high proportion of women in our study expressed willingness to participate in registries.…”

Improving Recruitment in Clinical Trials: Why Eligible Participants Decline

“…In addition, there were those who declined participation because they were solely interested in outpatient studies. These findings support the limited studies that have been done in the past, which also identified protocol issues such as preference for a specific treatment arm and fear of randomization (Penman et al, 1984; Llewellyn-Thomas et al, 1991; Jenkins et al, 1999) and the dislike of treatment being based on chance (Jenkins & Fallowfield, 2000) as reasons for declining participation.…”

What are potential barriers and enablers to patient and physician participation in Canadian cell therapy trials for stroke? A stakeholder interview study

“…Perhaps surprisingly, almost all patients expressed that inclusion of a placebo group would not impact their decision to participate. This is contrary to previous literature that has reported randomisation as a potential barrier to patient recruitment 9 10 27 28. Our finding may reflect the fact that chronic stroke is an under-researched area1 and, as a result, there is a strong appetite among patients to participate in evaluations of promising new therapies.…”